Sunday, May 28, 2017 11:41:21 AM
Yeah right, medical researchers in the academic world never offer to consult for money. You believe they do it for FREE?
Do you?
There's no sin for a doctor or professor to offer their consulting services to whomever wishes to pay them.
Ah, a diversion from Makowka to Simpson. Are we to do this for each one?
Who owns patent US20160244733 for the Melligen cells? Answer: University of Technology Sydney. Simpson listed as a co-inventor.
Who owns the patent combining Melligen cells with CIAB? Answer: None found. CIAB patent expired.
Oh, but they have a license from UTS to use the cells in CIAB. What do we know of the partnership agreement announced back in Jun 2015?
Wonder how Annie's research is coming along... The last research article she co-authored on Melligen cells was published in the "Molecular Therapy Methods Clinical Development" Journal, 08-Apr-2015. Where the UTS folks injected the Melligen cells directly into rats. This article was published before the partnership announcement with PMCB, and did not involve any CIABs. There's no further articles authored by her in the public domain. Ok, how about searching for research articles with "Melligen diabetes" - the same article pops up as the only hit. How about searching with "PharmaCyte diabetes" - no hits.
So here ya bee, 2 yrs later, and Annie hasn't published anything since 2015. In fact there is nothing published in the scientific journals with the word "PharmaCyte". Which means no one has used CIAB in their research, else they would've noted PMCB as the source. Or they used CIAB, and failed to get a positive result, which could be published.
Butt but but it's a secret! Well, no it isn't. It's called pre-clinical, and without published research, it goes nowhere with the FDA. So whatever happened to the pre-clinical, and drug trials involving Melligen calles +CIAB, PMCB jabbered about in the Aug 2015 10Q?
What we know 2 yrs later is that neither Annie, or anyone else published successful Melligen+CIAB results. The only thing that came out of the so called partnership is that PMCB got a few PR pumps.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Recent PMCB News
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 10:06:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:05:28 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/04/2023 08:40:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/04/2023 08:01:37 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 07/31/2023 09:18:17 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM